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Abstract
Background: Inhibitor of differentiation 2 (Id2) is a critical factor for cell proliferation and differentiation in
normal vertebrate development. Most of the biological function of Id2 has been ascribed to its helix-loop-helix
motif. Overexpression of Id2 is frequently observed in various human tumors, but its role for invasion potential
in tumor cells is dispute. We aimed to reveal the role of Id2 in invasion potential in poorly invasive and estrogen
receptor α (ERα)-positive MCF-7 and SKOV-3 cancer cells.
Methods: MCF-7 and SKOV-3 cells were stably transfected with the wild-type, degradation-resistant full-length
or helix-loop-helix (HLH)-deleted Id2, respectively. Protein levels of Id2 and its mutants and E-cadherin were
determined by western blot analysis and mRNA levels of Id2 and its mutants were determined by RT-PCR. The
effects of Id2 and its mutants on cell proliferation were determined by [3H]-thymidine incorporation assay and
the 3- [4, 5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) dye method. The in vitro invasion
potential of cells was evaluated by Transwell assay. Cell motility was assessed by scratch wound assay. The
promoter activity of E-cadherin was determined by cotransfection and luciferase assays.
Results: Ectopic transfection of the wild-type Id2 markedly increased the protein and mRNA expression of Id2
in MCF-7 and SKOV-3 cells; the protein level but not mRNA level was further increased by transfection with the
degradation-resistant Id2 form. The ectopic expression of Id2 or its mutants did not alter proliferation of either
MCF-7 or SKOV-3 cells. Transfection of the wild-type Id2 significantly induced the invasion potential and
migratory capacity of cells, which was further augmented by transfection with the degradation-resistant full-length
or HLH-deleted Id2. E-cadherin protein expression and transactivation of the proximal E-cadherin promoter
were markedly suppressed by the degradation-resistant full-length or HLH-deleted Id2 but not wild-type Id2.
Ectopic expression of E-cadherin in MCF-7 and SKOV-3 cells only partially blunted the invasion potential induced
by the degradation-resistant HLH-deleted Id2.
Conclusion: Overexpression of Id2 in ERα-positive epithelial tumor cells indeed increases the cells' invasive
potential through a novel mechanism independent of dimerization to basic helix-loop-helix factors. E-cadherin
contributes only in part to Id2-induced cell invasion when Id2 is accumulated to a higher level in some specific cell
types.
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Background
Tumor metastasis is the highest cause of death in cancer
patients. In carcinomas, the metastasis is thought to be a
complex biological process. The first crucial step is the
movement of cancer cells into tissue surrounding the
tumor and vasculature [1]. During this step, a small pro-
portion of epithelial tumor cells lose cell-cell adhesion
and gain higher mobility, thus allowing them to invade
the adjacent tissues [2,3]. Hence, the molecular events
that contribute to the increased motility of tumor cells has
become important for understanding tumor metastasis as
well as for targets for potential therapeutic intervention in
human cancers. Both human breast cancer MCF-7 and
human ovarian carcinoma SKOV-3 cells are estrogen-
receptor α (ERα)-positive epithelial tumor cell lines. They
are usually used as experimental cell models because of
their poorly invasive capacity [4,5]. These cell models are
helpful for exploring genes aberrantly expressed in tumor
cells that contribute to tumor metastasis [6-8].
Inhibitor of differentiation 2 (Id2) is one of the four
members of the Id protein family [9]. In normal organ-
isms, Id proteins are key regulators in development. They
control lineage determination, differentiation, and prolif-
eration in a variety of diverse cell types by regulating tran-
scriptional networks [9-11]. Id mRNA and protein levels
are elevated in diverse human tumor types [12-14]. By
fueling several key features of tumor progression, includ-
ing deregulated proliferation, invasiveness and metastasis,
Id proteins contribute to multiple steps of tumorigenesis
[13,15]. Although the general role of Id2 proteins has
been considered pro-growth and anti-differentiation in
various human tumors [13-15], their role in modulating
invasion and metastasis of some specific tumor cells
remain to be investigated.
All members of the Id protein family share a similar struc-
ture consisting of a highly conserved helix-loop-helix
(HLH) domain [11]. Apart from the HLH structure, both
the NH2 and COOH region sequences vary greatly among
Ids [16]. The growing interest in the biology of Id proteins
during the past decades has not substantially modified the
primary function of "inhibitor of DNA binding" as origi-
nally assigned in 1990 [17]. This function has been
ascribed to the HLH sequence motif, which mediates het-
erdimerization with the basic HLH (bHLH) transcription
factors, ETS and PAX-DNA binding proteins, and retino-
blastoma (Rb) tumor suppressor protein [17-20]. When
engaged by Id proteins, the transcription factor is no
longer able to bind to DNA target sequences and activate
transcription. Although the HLH motif of Id2 lies at the
center of a molecular network controlled by Id2, evidence
suggests that Id2 performs its HLH-independent function
prominently in some specific cell types. For example, in
both interleukin-3 (IL-3)-dependent 32D.3 myeloid pro-
genitors and U2OS osteosarcoma cells, the non-HLH
region of Id2 performed a prominent apoptosis-promot-
ing function [21].
Id2 protein is very unstable in cells. It contains a canonical
D-box motif (RxxLxxxN) at residues 100 to 107. Recently,
expression of Id2 with D-box mutation was found to be
resistant to APC/CCdh1-mediated degradation in cells, sub-
sequently extending the half-life of Id2 to more than 10-
fold that of the wild-type Id2 [22]. Thus, ectopic expres-
sion of the degradation-resistant form of Id2 protein in
certain tumor cell types might provide beneficial effects
for displaying Id2-mediated signaling and phenotypic
traits, which might easily be overlooked with transfection
of wild-type Id2.
We aimed to reveal the role of Id2 and its degradation-
resistant mutants in cell invasiveness and migration in
poorly invasive MCF-7 and SKOV-3 cancer cells positive
for ERα. We were particularly interested in whether the
HLH feature of Id2 was implicated in the Id2 function and
the Id2 protein effect on the metastasis suppressor E-cad-
herin. Ectopic expression of the wild-type human Id2
markedly increased the in vitro invasion capacity of MCF-
7 and SKOV-3 cancer cells, which was further augmented
by transfection with the degradation-resistant form of Id2.
Strikingly, the HLH-deleted Id2 form could also signifi-
cantly increase cell invasiveness and migration, which
indicates that the invasion-promoting role of Id2 is inde-
pendent of its ability to dimerize with bHLH members.
The invasion potential induced by Id2 was only partially
associated with the down-regulation of the metastasis
suppressor E-cadherin, suggesting that multiple molecules
associated with tumor metastasis may be implicated in
this process.
Methods
Plasmid constructs
The full-length coding region of the wild-type human Id2
in plasmid pLXSN [23], was obtained from Prof. Desprez
(California Pacific Medical Center, San Francisco, CA).
The plasmid pcDNA3-Id2-DBM containing the complete
coding sequence of the full-length human Id2 with D-box
mutation was kindly donated by Prof. Iavarone (Colum-
bia University Medical Center, New York) [22]. The luci-
ferase reporter gene construct (E-cadK1-Luc) containing
the E-cadherin sequence and its mutants (E-cadK1-Luc-E-
boxA, E-cadK1-Luc-E-boxB and E-cadK1-Luc-E-boxC)
were provided by Dr. Eric R Fearon (University of Michi-
gan Medical School, Ann Arbor, MI). The E-cadherin
expression vector was described previously [8]. The Id2-
DBM-δHLH fragment, lacking the entire HLH domain
(codons 35 to 76 aa), was derived from pcDNA3-Id2-
DBM by a sequential PCR scheme. In PCR reaction A,
pcDNA3-Id2-DBM was amplified with 5'-atgaaagcct-BMC Cancer 2009, 9:75 http://www.biomedcentral.com/1471-2407/9/75
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tcagtcccgt-3' and 5'-gtccagggcgatcaggctcatcgggtcg-3' as the
upstream and downstream primers, respectively, to give a
117-bp fragment. In PCR reaction B, pcDNA3-Id2-DBM
was amplified with 5'-ccgatgagcctgatcgccctggactcgc-3' and
5'-ttagccacacagtgctttgc-3' as the upstream and downstream
primers, respectively, to give a 189-bp fragment. Aliquots
of each PCR product were purified after agarose gel elec-
trophoresis and combined to serve as a template for a final
PCR with the use of the PCR A upstream primer and the
PCR B downstream primer. The 282-bp PCR product was
then subcloned into Hind  III and BamH  I sites of
pcDNA3.1 to generate pcDNA3.1-Id2-DBM-δHLH. The
full-length Id2 cDNA derived from pLXSN-Id2 was sub-
cloned into pcDNA3.1 at BamH I and Xho I sites to gener-
ate pcDNA3.1-Id2. The Id2-DBM fragment from pcDNA3-
Id2-DBM was amplified by PCR and subcloned into
pcDNA3.1 at BamH  I and Xho  I sites to generate
pcDNA3.1-Id2-DBM. All constructs were confirmed by
restriction enzyme mapping and DNA sequencing.
Cell culture
The human breast cancer cell line MCF-7 and ovarian can-
cer cell line SKOV-3 were obtained from the American
Type Culture Collection (ATCC, Rockville, MD). MCF-7
cells were maintained as monolayer cultures in Dul-
becco's modified Eagle's medium (DMEM; Gibco, New
York) supplemented with 10% fetal bovine serum (FBS;
Hyclone, UT), 100 U/ml penicillin G and 100 μg/ml
streptomycin. SKOV3 cells were maintained in RPMI1640
(Gibco) containing 10% FBS, 100 U/ml penicillin G and
100 μg/ml streptomycin in a humid atmosphere with 5%
CO2 at 37°C.
Cell transfection and small interfering RNA (siRNA)
MCF-7 and SKOV3 cells were seeded in 60-mm culture
dishes before transfection. When the cell confluence
reached 40–60%, cells were stably transfected with 5 μg
pcDNA3.1-Id2, pcDNA3.1-Id2-DBM or pcDNA3.1-Id2-
DBM-δHLH by use of the Superfect transfection reagent
(Qiagen, Hilden, Germany), according to the manufac-
turer's instructions. The empty vector was used as a nega-
tive control. Two days post-transfection, MCF-7 cells were
treated with 1000 μg/ml G418 (Gibco) and SKOV3 cells
with 1 mg/ml G418 for 10–14 d and then were continu-
ously cultured with 400 μg/ml G418.
For siRNA transfection, MCF-7 cells stably expressing Id2-
DBM were seeded in 60-mm culture dishes and grown to
80% confluence. An amount of 4 μg siRNA duplexes were
transiently cotransfected with use of Lipofectamine 2000
according to the manufacturer's recommendations (Invit-
rogen, Carlsbad, CA). Oligonucleotides for siRNA were
chemically synthesized by Shanghai GeneChem Co.
(Shanghai, China). The human Id2-specific siRNA, 5'-
cacggatatcagcatcctg-3' (sense strand), corresponds to 504
to 522 bp (accession no. NM_002166) [24]. The unre-
lated siRNA sequence (sense strand, 5'-ttctccgaacgtgcacgt-
3') was used as a control.
Western blot analysis
The expression of Id2, E-cadherin and β-actin proteins
was examined by western blot analysis as described previ-
ously [8]. Antibodies were monoclonal rabbit anti-Id2
antibody (1:500, Invitrogen), polyclonal rabbit anti-E-
cadherin antibody (1:300, Santa Cruz Biotechnology),
polyclonal Flag antibody (1:500, Sigma) or polyclonal
rabbit anti-β-actin antibody (1:500, Santa Cruz Biotech-
nology). Blots were probed with the primary antibodies,
washed and then incubated with horseradish peroxidase-
labeled secondary antibodies (Santa Cruz Biotechnol-
ogy), and binding was detected using enhanced chemilu-
minesence.
RT-PCR
Total RNAs were extracted by the acid guanidium thiocy-
anate-phenol chloroform method with TriBlue reagent
purchased from Tiangen Bio. (Beijing). cDNA was pre-
pared with Superscript III RNase H- reverse transcriptase
(Invitrogen) and 2–5 μg of total RNA. The PCR primer sets
5'-atgaaagccttcagtcccgt-3' (sense) and, 5'-ttagccacagt-
gctttgc-3' (antisense) were used for amplifying Id2 and its
derivatives. GAPDH was used as internal control with the
following primer sets: forward primer, 5'-aaggtcggagt-
caacggatt-3', and reverse primer, 5'-catgagtccttcacgatac-3'.
The PCR products were fractionated by electrophoresis on
a 1.5% agarose gel containing 0.5% ethidium bromide.
Cell proliferation assays
Assay fro [3H]-thymidine incorporation (Yahui, Co. Bei-
jing) and the 3- [4, 5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (MTT) dye method were used to
assess cell proliferation. For thymidine incorporation,
cells in logarithmic growth phase were detached by use of
0.25% trypsin and seeded in 24-well plates in culture
media with 10% FBS (1 × 104/well). Media was changed
every 24 h during the experiment. [3H]-thymidine (2 μCi)
was added to fresh medium and incubated with cells for 1
h at 37°C. Cells were then washed, methanol fixed, and
solubilized prior to scintillation counting. For MTT assays,
3 × 103 viable cells were plated in 96-well plates with cul-
ture medium containing 10% FBS. After incubation for 12
h, the medium was replaced with fresh medium contain-
ing 1% FBS and 400 μg/ml G418 for 6 or 8 days. Media
was changed every 24 h during the experiment. MTT labe-
ling reagent was added to fresh medium and incubated
cells for 4 h at room temperature. Absorbance was exam-
ined at 590 nm by use of a microplate reader.BMC Cancer 2009, 9:75 http://www.biomedcentral.com/1471-2407/9/75
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Transwell assay (Boyden chamber invasion assay)
Invasion assays were carried out in modified Boyden
chambers with 8-μm pore filter inserts for 24-well plates
(BD Transduction) as described [8]. Briefly, the surfaces of
the filters were coated with 15 μl ice-cold Matrigel (15 mg/
ml protein; BD Tranduction) for 60 min at room temper-
ature. Uniformity of the coating was checked by Coomas-
sie blue staining and low-power microscopy observation.
The lower chamber was filled with medium containing
10% serum. Fibronectin (16 μg/chamber) was added as
the chemoattractant to the lower chamber. Cells (1 × 105
cells/well) were washed with 1 × PBS twice, re-suspended
in 200 μl of serum-free medium and then transferred into
the upper chamber. After 24 h of incubation, the filter was
gently removed from the chamber, the cells on the upper
surface were removed by wiping with a cotton swab, and
cells that had invaded to the lower surface areas were
fixed, stained with hematoxylin and eosin (H&E) and
counted in 15 randomly selected fields on microscope
(×100). Experiments were performed independently at
least three times.
Cell migration assay
Cell motility was assessed by scratch-wound assay as
described previously [4]. The cells were seeded into 60-
mm culture dishes at 2.5 × 105 cells and cultured in
medium containing 10% FBS to nearly confluent cell
monolayers, which were then carefully wounded by use of
a 200-μl sterile pipette tip, and any cellular debris was
removed by washing with PBS. The wound monolayers
were then incubated in medium containing 10% FBS for
24 h and photographed under a light microscope (×200).
The experiments were repeated in triplicate wells at least
three times. The area of migrating cells was estimated by
counting the number of pixels after the photographs had
been converted to photoshop data (Adobe, San Jose, CA).
Luciferase reporter assays
Cells at 50% confluence in 35-mm dishes were transfected
by use of Superfect reagent. An amount of 1 μg of E-cad-
herin promoter gene construct (E-cadK1-Luc) or the E-box
mutant construct and 1 μg of Id2 or its mutants were
cotransfected. pRL-SV40 (Promega, Madison, WI) was
used as an inner control (1 ng/well). Cell extracts were
prepared 42 h after transfection, and the luciferase activity
was measured by the Dual-Luciferase Reporter Assay Sys-
tem (Promega) as described previously [8]. All experi-
ments were performed in triplicate and repeated three
times.
Statistical analysis
Data are expressed as mean ± S.E.M. Statistical differences
were determined by use of the Chess software and Stu-
dent's t test. P < 0.05 was considered statistically signifi-
cant.
Results
Stable expression of Id2 and its mutants in MCF-7 and 
SKOV-3 cells
To investigate the effects of overexpression of Id2 and its
mutants on the phenotypic traits of MCF-7 and SKOV-3
cells, the expression plasmids for Id2, Id2-DBM, and Id2-
DBM-δHLH (schematic structure illustrated in Figure 1A)
or the empty control vector were stably transfected into
cells. After 10- to 14-day G418 screening, the drug-resist-
ant clones appeared and were mixed for amplified culture.
All of the parental cells were killed by G418 within this
period. On western blot analysis, endogenous Id2 protein
was not detected in MCF-7 cells and weakly detected in
SKOV-3 cells, but ectopic transfection of Id2 markedly
increased the expression of Id2 protein in both cell lines
(Figure 1B). Ectopic transfection of D-box mutant Id2 fur-
ther increased Id2 protein expression 2 to 3-fold that of
transfection with the wild type Id2. A band corresponding
to HLH-deleted Id2-DBM was detected using a rabbit anti-
Id2 monoclonal antibody. Next, we further measured the
mRNA levels of Id2 and its mutants in transfected cells by
RT-PCR (Figure 1C) and found the mRNA expression of
Id2 are consistent with protein levels in empty vector- and
wild-type Id2-transfected cells. However, the mRNA level
with Id2-DBM transfection did not differ from that with
wild-type Id2 transfection in either MCF-7 or SKOV-3
cells. Id2-DBM-δHLH mRNA could be detected in cells,
which confirms the effective expression of the HLH-
deleted Id2. Collectively, these data indicated that the
ectopic Id2 and its mutants can effectively be expressed in
MCF-7 and SKOV-3 cells and with the D-box mutation
transfection, Id2 protein could accumulate to a much
higher level than with the wild type.
Overexpression of Id2 and its mutants does not promote 
proliferation of MCF-7 or SKOV-3 cells
Overwhelming evidence favors the view that Id proteins
are essential proliferative factors for a large variety of cell
types [9,10]. To determine whether overexpression of Id2
and its mutants promotes proliferation of MCF-7 and
SKOV-3 cells, we performed [3H]-thymidine incorpora-
tion and MTT assays and revealed that transfection of Id2
and its mutants did not significantly alter proliferation of
either cell line (Figure 2A and 2B).
Overexpression of Id2 and its mutants promotes the in 
vitro invasion and motility of MCF-7 and SKOV-3 cells
To examine the effects of Id2 and its mutants on the inva-
sive capacity of MCF-7 and SKOV-3 cells, we performed a
modified Boyden chamber assay to determine the ability
of cells to invade through biological matrices in vitro. The
relevance of this assay for other invasive assays and for in
vivo malignancy has been documented extensively [25].
Both MCF-7 and SKOV-3 are poorly invasive cell lines, but
their invasion potential is moderately increased in theBMC Cancer 2009, 9:75 http://www.biomedcentral.com/1471-2407/9/75
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presence of fibronectin as the chemoattractant. The inva-
sion of cells with ectopic transfection of wild-type Id2 or
its two mutants was higher than that of the control cells
(Figure 3, left panel). In contrast to mock transfection, Id2
transfection produced a 40% and 50% increase of the
invasiveness of MCF-7 and SKOV-3 cells, respectively (Fig-
ure 3, right panel). Unexpectedly, such invasion was aug-
mented to a higher level by Id2-DBM or Id2-DBM-δHLH
transfection in both cell lines with an increase in invasive-
ness of 90% and 70% for MCF-7 cells and 110% and 78%
for SKOV-3 cells with Id2-DBM and Id2-DBM-δHLH
transfection, respectively (Figure 3). These results pointed
(A) Schematic illustration of the Id2-DBM-δHLH construct Figure 1
(A) Schematic illustration of the Id2-DBM-δHLH construct. In this construct, the HLH domain encoded by amino acid 
residues from 35 to 76 was deleted from Id2, and the key arginine and leucine residues within the D-box motif (RxxLxxxN) at 
residues 100 to 107 were changed to glycine and valine. (B) Western blot analysis of Id2 and its mutants in MCF-7 and 
SKOV-3 cells. Total proteins were extracted from cells transfected with the indicated plasmids, and then underwent SDS-
PAGE electrophoresis and immunoblotting analysis using the indicated antibodies. β-actin was used as the loading control. (C) 
RT-PCR analysis of Id2 and its mutants in MCF-7 and SKOV-3 cells. Total RNA was extracted from cells transfected 
with the indicated plasmids and used for RT-PCR analysis of the mRNA expression of Id2 and its mutants. β-actin was the load-
ing control. The results shown in B and C are representative of three independent experiments.
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(A) Effect of overexpression of Id2 or its mutants in MCF-7 and SKOV-3 cells on [3H] thymidine incorporation into cellular  DNA Figure 2
(A) Effect of overexpression of Id2 or its mutants in MCF-7 and SKOV-3 cells on [3H] thymidine incorporation 
into cellular DNA. The indicated cells transfected with the indicated plasmids were seeded in 24-well plates in culture media 
with 10% FBS (1 × 104/well). At the indicated times, [3H]-thymidine (2 μCi) was added to fresh medium and incubated for 1 h 
at 37°C prior to scintillation counting. Experiments at each time point were performed in triplicate, and the graph is represent-
ative of three independent experiments. (B) Effect of overexpression of Id2 or its mutants on proliferation rate of 
MCF-7 and SKOV-3 cells. The indicated cells transfected with the indicated plasmids were cultured in triplicate, and MTT 
assay was performed at the indicated times. Absorbance was examined at 590 nm by use of a microplate reader. Data are 
mean ± SEM for at least three separate determinations. CPM = counts per million; OD = optical density.
(a)
(b)BMC Cancer 2009, 9:75 http://www.biomedcentral.com/1471-2407/9/75
Page 7 of 14
(page number not for citation purposes)
to a linear link between the invasive capacity of MCF-7
and SKOV-3 cells and Id2 expression level and also indi-
cate that this functional link did not depend on the pres-
ence of HLH domain of Id2. Overexpression of the HLH-
deleted Id2 induced a significant increase in invasiveness
of MCF-7 and SKOV-3 cells.
To further address the promotion role of Id2 overexpres-
sion on cell invasiveness, Id2-specific siRNA or control-
siRNA oligonucleotides was transiently transfected into
MCF-7 cells stably expressing Id2-DBM or pcDNA3.1
empty vector. Forty-eight hours later, cells were harvested
and subjected to western blot analysis and Transwell
experiments. The expression of ectopic Id2-DBM protein
was largely inhibited by the Id2-specific siRNA but not by
control-siRNA (Figure 4A). Knock down of exogenous
Id2-DBM in MCF-7 cells by Id2-specific siRNA cotransfec-
tion reduced the cell invasiveness enhanced by Id2-DBM
to that of the control cells (Figure 4B).
To examine whether the invasion potential of MCF-7 and
SKOV-3 cells promoted by Id2 and its mutants was asso-
ciated by their increase in cell motility, we analyzed the
effects of Id2 and its mutants on the migration capability
of cells by observing the effects of scratch wounding con-
fluent monolayers of cells transfected with Id2 or its
mutants. Overexpression of the wild-type Id2 or its
mutants markedly promoted the flattening and spreading
of both cell lines along the edges of the wound as com-
pared with the control (Figure 5).
Id2 mutants but not the wild-type Id2 inhibit the 
expression and transcriptional activity of E-cadherin gene 
in MCF-7 and SKOV-3 cells
E-cadherin (encoded by the CAD1 gene in humans) is a
cell-surface glycoprotein involved in calcium-dependent
cell-cell adhesion [26]. The increased invasion and migra-
tory capacity of epithelial tumor cells are always associ-
ated with reduced level of E-cadherin [27-29]. To ascertain
whether Id2-induced increase of in vitro invasiveness and
migration of MCF-7 and SKOV-3 cells is accompanied by
changes in E-cadherin, we analyzed the protein expression
of E-cadherin by western blot assay. Transfection of the
wild-type Id2 did not significantly change the expression
Effect of overexpression of Id2 or its mutants on the in vitro invasion of MCF-7 and SKOV-3 cells Figure 3
Effect of overexpression of Id2 or its mutants on the in vitro invasion of MCF-7 and SKOV-3 cells. The left panel is 
representative pictures of Transwell assays, performed for the indicated cells as described in "Methods". Each experiment was 
performed in triplicate and was repeated three times. Data are expressed as the percentage of the control cells (mean ± SEM, 
the bottom panel). (*P < 0.05; # P <0.01; N P > 0.05).
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(A) Effect of Id2-specific siRNA transfection on the expression of the exogenous Id2-DBM protein in MCF-7 cells Figure 4
(A) Effect of Id2-specific siRNA transfection on the expression of the exogenous Id2-DBM protein in MCF-7 
cells. The indicated siRNA oligonucleotides were transfected into the indicated MCF-7 cells. 48 h after transfection, total pro-
teins were extracted and subjected to immunoblotting analysis with Id2-specific antibody. β-actin was used as the loading con-
trol. (B) Effect of knock down of exogenous Id2-DBM by RNA interference on in vitro invasion of MCF-7 cells. 
The indicated siRNA oligonucleotides were transfected as described in (A). 48 h after transfection, MCF-7 cells were subjected 
to performing Transwell experiments. The top panel shows representative pictures of Transwell assays, as described in "Meth-
ods". Each data was performed in triplicate and was repeated three times. Data are expressed as the percentage of the control 
cells (mean ± SEM, the bottom panel). (# P <0.01; N P > 0.05).
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Effect of overexpression of Id2 or its mutants on the migratory capacity of MCF-7 and SKOV-3 cells Figure 5
Effect of overexpression of Id2 or its mutants on the migratory capacity of MCF-7 and SKOV-3 cells. Migratory 
behaviors of Id2 or its mutant transfectants were determined by scratch-wound assay (top panel) and quantified as described in 
"Methods" (bottom panel). The scratch area at 0 h was arbitrarily assigned as 100%. (*P < 0.05; # P <0.01; N P > 0.05).
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of E-cadherin protein in either cell line (Figure 6A); how-
ever, transfection with Id2-DBM or Id2-DBM-δHLH
caused a 2- to 5-fold decrease of E-cadherin protein
expression as compared with the mock transfection in
both cell lines. Next, to determine whether the Id2
mutants are repressors of transcriptional activity of E-cad-
herin gene, the promoter construct of E-cadherin, Id2 or
either of its mutants were cotransfected into MCF-7 and
SKOV-3 cells. Since the proximal E-cadherin promoter was
shown to mainly confer the transcriptional inactivation of
E-cadherin in some cancer cell lines [30-33], we used the
most proximal E-cadherin  human promoter construct
(EcadK1-Luc, -108 to +125), which contained three E-box
elements. E-cadK1-Luc activities were efficiently repressed
(A) Effect of overexpression of Id2 or its mutants on E-cadherin protein expression Figure 6
(A) Effect of overexpression of Id2 or its mutants on E-cadherin protein expression. Total proteins were extracted 
from the indicated cells for analysis of E-cadherin protein by western blot. (B) Effect of overexpression of Id2 or its 
mutants on the transactivation of E-cadherin gene promoter. The indicated cells were transiently cotransfected with 
the indicated plasmids for luciferase assay as described in "Methods". Data are expressed as mean ± SEM for at least three sep-
arate determinations.
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by Id2-DBM and Id2-DBM-δHLH (2- to 2.5- fold) but not
by the wild-type Id2 (Figure 6B). Thus, excessive accumu-
lation of Id2 by abolishing its degradation in MCF-7 and
SKOV-3 cells represses the expression of E-cadherin gene
by inhibiting its transactivation. As well, this repression is
not dependent on the HLH domain of Id2.
To identify whether the E-box contained within the prox-
imal region of E-cadherin promoter is responsive to HLH-
deleted Id2-DBM, we used E-box A, B or C mutant con-
structs and Id2-DBM-δHLH to cotransfect MCF-7 cells for
luciferase assays. Mutation of E-box B or E-box C but not
A significantly attenuated the repression of the reporter
gene activity by Id2-DBM-δHLH (Figure 7A), which sug-
gests that the E-box-binding transcription repressors are
involved in HLH domain-independent Id2 repression of
E-cadherin transactivation.
To test whether the induction of the cells' invasion capac-
ity by Id2-DBM-δHLH overexpression is attributed to the
down-regulation of E-cadherin, the E-cadherin expression
vector or pcDNA3.1 empty plasmid was transiently trans-
fected into Id2-DBM-δHLH-overexpressing MCF-7 and
SKOV-3 cells. Immunoblotting analysis showed E-cad-
herin protein level augmented in E-cadherin-transfected
cells (Figure 7B, left panel,). Although the invasiveness of
transfectants with Id2-DBM-δHLH plus E-cadherin was
significantly higher than that of the empty-vector trans-
(A) Effect of E-box mutagenesis on Id2-DBM-δHLH repression of E-cadherin promoter reporter activity Figure 7
(A) Effect of E-box mutagenesis on Id2-DBM-δHLH repression of E-cadherin promoter reporter activity. MCF-7 
cells were transiently cotransfected with the indicated plasmids for luciferase assay as described in "Methods". Data are 
expressed as mean ± SEM for at least three separate determinations. (B) Effect of ectopic E-cadherin expression on Id2-
DBM-δHLH-induced cell invasion potential. E-cadherin expression vector or the corresponding empty vector was tran-
siently transfected into Id2-DBM-δHLH stably expressed or wild-type MCF-7 and SKOV-3 cells for immunoblotting analysis 
with the indicated antibodies (left panel) and Transwell assays (right panel). Data are expressed as the percentage of the con-
trol cells (mean ± SEM). (# P <0.01; N P > 0.05).
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fectants, the ectopic expression of E-cadherin in both
MCF-7 and SKOV-3 cells could partially blunt the inva-
sion potential induced by Id2-DBM-δHLH (Figure 7B,
right panel,). Thus, down-regulation of E-cadherin expres-
sion is responsible only in part for the HLH domain-inde-
pendent Id2-enhanced invasion, and over-accumulated
Id2 could induce other unknown signaling through its
non-HLH region to promote cell invasion.
Discussion
Tumor progression is the evolution of already tumori-
genic cells towards increasing malignancy [1,2]. During
tumor progression, further aberrant molecular events may
occur in a specialized subset of low invasive cancer cells
and ultimately promote these cells to acquire the ability of
highly invasive growth [3]. Identification of the molecules
that predispose tumor cells to a more invasive phenotype
is helpful for understanding the tumor metastasis process
as well as providing potential therapeutic targets for
tumor progression. In this study, we manipulated Id2
expression in poorly invasive MCF-7 and SKOV-3 cancer
cells and determined the effects on cell proliferation, in
vitro invasion and migration. Id2 could facilitate the inva-
sive and migratory capabilities of MCF-7 and SKOV-3 cells
in a dose-dependent manner. Importantly, structure and
function analyses revealed that the HLH domain of Id2 is
not required for its pro-invasive function. These observa-
tions suggest that the aberrant accumulation of Id2 in
some specific non-aggressive epithelial tumor cells may be
sufficient to convert them into more invasive cells.
Elevated levels of Id2 expression have been reported in
carcinomas of breast, ovary, colon and prostate, in neural
tumors, melanoma, Ewing's sarcoma and in hematologi-
cal malignancies [13-15]. In some cases, high levels of Id2
expression are associated with disease severity and poor
prognosis. However, significant contradictions exist in
various types of human tumors. In addition, cell-based
experiments indicated that Id2 has diverse and complex
biological effects depending on cell lineage, differentia-
tion state, and other contextual considerations [24]. For
example, down-regulation of Id2 expression in highly
metastatic PC-3 human prostate cancer cells reduced their
growth potential and invasiveness, which indicates the
pro-proliferation and pro-invasion roles of Id2 in some
epithelial cancer cells [34]. Conversely, ectopic expression
of Id2 in MDA-MB-231 and MDA-MB-436 human breast
cancer cells did not significantly affect cell growth but
markedly reduced the cells' invasive capacity [23,35].
These controversial functional consequences of Id2 on
tumor growth and invasion suggest the diverse nature of
Id2 target signaling pathways in different cell contexts.
Therefore, careful evaluation is required to unambigu-
ously identify the tumor cell types or subtypes that may
use Id2 to control their different phenotypes. Although
MCF-7 is also a human breast cancer cell line, its genetic
background and phenotypic characteristics differ greatly
in MDA-MB-231 and MDA-MB-436 cells. Generally, the
MCF-7 cell line is representative of ERα-positive and non-
aggressive human breast cancers; however, MDA-MB-231
and MDA-MB-436 are representative of ERα-negative
breast cancer cells. In addition, SKOV-3 is an ovarian car-
cinoma cell line with ERα-positive and non-aggressive
phenotypes. In this study, overexpression of Id2 or either
of its two mutants increased the invasive capacity of MCF-
7 and SKOV-3 cells but did not alter the proliferation of
either of these two cell lines. The functional role of Id2 in
the cell invasion phenotype in MCF-7 and SKOV-3 cells is
completely contrary to that previously observed in MDA-
MB-231 and MDA-MB-436 cells. Considering the expres-
sion of ERα in MCF-7 and SKOV-3 cells, we postulated
that the aberrant Id2 expression may play an important
role in converting ERα-positive epithelial tumor cells into
highly invasive cells. Although a high expression of Id2 in
primary breast cancer cells was reported to confer favora-
ble clinical outcome [35], our findings suggest that the
analysis of Id2 expression in combination with ERα status
may be better for prognostic reevaluation of breast cancer.
Our important finding is that the HLH domain of Id2 is
not required for the pro-invasive activity of the protein
and that the level of expression of an invasion-suppress-
ing molecule, E-cadherin, is down-regulated by only the
degradation-resistant Id2 form. These observations raise
the possibility that different expression levels of Id2 can
influence different gene expression through a heretofore
unknown transcriptional activity of its non-HLH region.
Consistent with this is our observation that the transacti-
vation of E-cadherin promoter is significantly suppressed
by the degradation-resistant full-length and HLH-deleted
Id2 forms but not the wild-type form. Although MCF-7
and SKOV-3 cells are highly sensitive to changes in the lev-
els of E-cadherin and will undergo enhanced invasion if E-
cadherin is down-regulated, supplementation of E-cad-
herin in cells does not completely antagonize the invasion
potential induced by Id2-DBM-δHLH. Overexpression of
the wild-type Id2 in MCF-7 and SKOV-3 cells did not
reduce E-cadherin expression but did indeed promote the
invasion and migration of both cell lines. So, different
mechanisms are involved in the invasion potential
induced by different Id2 expression levels in cells.
Previous studies have linked Id and E-cadherin expression
in some specific cell types. Id proteins have been shown to
activate E-cadherin in normal epithelial cells by inhibiting
E2A protein, which represses the most proximal E-cad-
herin promoter in these cells through interaction with the
E-box elements [36,37]. However, apparent contradiction
exists in some specific cell types. For example, in uveal
melanoma Mel202 and Mel290 cells, Id2 suppressed E-BMC Cancer 2009, 9:75 http://www.biomedcentral.com/1471-2407/9/75
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cadherin expression through inhibiting the transactiva-
tion of its proximal promoter by an unknown regulatory
mechanism [33]. In this study, Id2 suppressed E-cadherin
expression in MCF-7 and SKOV-3 cells through a mecha-
nism independent of its dimerization to bHLH factors
when Id2 was accumulated to a high level in cells.
E-cadherin is often positive in ERα-positive cancer cells
and often negative in ERα-negative tumor cells (such as
MCF-7 versus MDA-MB-231 cells), and loss of E-cadherin
may result in the more aggressive growth of ERα-positive
cells by increasing the probability of invasion and metas-
tasis [26]. Epithelial cancers arise within an epithelium
where cells are constrained by E-cadherin-mediated cell-
cell interactions. Hence, in the early stages of these can-
cers, E-cadherin must be down-regulated to escape the
local epithelial environment and invade local structures.
In this paradigm, the aberrant accumulation of Id2 and
the subsequent E-cadherin down-regulation as we
described should provide a selective growth advantage in
the tumor microenvironment by increasing the probabil-
ity of invasion and metastasis.
Conclusion
In summary, in our analyses of the expression of Id2 and
its mutants in ERα-positive MCF-7 and SKOV-3 cells,
aberrant accumulation of Id2 in certain ERα-positive epi-
thelial tumor cells indeed increased the cells' invasive
potential through a novel mechanism independent of
dimerization to bHLH factors and E-cadherin partially
contributes to Id2-induced cell invasion in an HLH
domain-independent manner when Id2 is accumulated to
a high level in some specific cell types.
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